This HTML document was obtained by processing the OWL ontology source code through LODE, Live OWL Documentation Environment, developed by Silvio Peroni .

Table of Content

Classes

1,1,1-trichloro-2,2-bis(4-chlorophenyl)ethane degradation pathwayc back to ToC or Class ToC

1,2-dichloroethane degradation pathwayc back to ToC or Class ToC

11-beta-hydroxylase deficiency pathwayc back to ToC or Class ToC

17-alpha-hydroxylase deficiency pathwayc back to ToC or Class ToC

2,4-dichlorobenzoate degradation pathwayc back to ToC or Class ToC

2-aminoadipic 2-oxoadipic aciduria pathwayc back to ToC or Class ToC

2-hydroxyglutaric aciduria pathwayc back to ToC or Class ToC

21-alpha-hydroxylase deficiency pathwayc back to ToC or Class ToC

3'-end pre-mRNA processing pathwayc back to ToC or Class ToC

3-chloroacrylic acid degradation pathwayc back to ToC or Class ToC

3-hydroxy-3-methylglutaryl-CoA lyase deficiency pathwayc back to ToC or Class ToC

3-hydroxyacyl-CoA dehydrogenase deficiency pathwayc back to ToC or Class ToC

3-hydroxyisobutyric aciduria pathwayc back to ToC or Class ToC

3-methylcrotonyl CoA carboxylase 1 deficiency pathwayc back to ToC or Class ToC

3-methylcrotonyl CoA carboxylase 2 deficiency pathwayc back to ToC or Class ToC

3-methylglutaconic aciduria type 1 pathwayc back to ToC or Class ToC

3-methylglutaconic aciduria type 3 pathwayc back to ToC or Class ToC

5'-end pre-mRNA capping pathwayc back to ToC or Class ToC

<new term>c back to ToC or Class ToC

<new term>c back to ToC or Class ToC

<new term>c back to ToC or Class ToC

abacavir drug pathwayc back to ToC or Class ToC

abacavir pharmacodynamics pathwayc back to ToC or Class ToC

abacavir pharmacokinetics pathwayc back to ToC or Class ToC

abciximab drug pathwayc back to ToC or Class ToC

abciximab pharmacodynamics pathwayc back to ToC or Class ToC

abciximab pharmacokinetics pathwayc back to ToC or Class ToC

abscisic acid biosynthetic pathwayc back to ToC or Class ToC

abscisic acid metabolic pathwayc back to ToC or Class ToC

ACE inhibitor drug pathwayc back to ToC or Class ToC

ACE inhibitor pharmacodynamics pathwayc back to ToC or Class ToC

ACE inhibitor pharmacokinetics pathwayc back to ToC or Class ToC

acebutolol drug pathwayc back to ToC or Class ToC

acebutolol pharmacodynamics pathwayc back to ToC or Class ToC

acebutolol pharmacokinetics pathwayc back to ToC or Class ToC

acenocoumarol drug pathwayc back to ToC or Class ToC

acenocoumarol pharmacodynamics pathwayc back to ToC or Class ToC

acenocoumarol pharmacokinetics pathwayc back to ToC or Class ToC

acetylcholine metabolic pathwayc back to ToC or Class ToC

acetylcholine signaling pathwayc back to ToC or Class ToC

acetylcholine signaling pathway via muscarinic acetylcholine receptorc back to ToC or Class ToC

acetylcholine signaling pathway via muscarinic acetylcholine receptors engaging G alphai protein familyc back to ToC or Class ToC

acetylcholine signaling pathway via muscarinic acetylcholine receptors engaging G alphaq protein familyc back to ToC or Class ToC

acetylcholine signaling pathway via nicotinic acetylcholine receptorc back to ToC or Class ToC

acetylsalicylic acid drug pathwayc back to ToC or Class ToC

acetylsalicylic acid pharmacodynamics pathwayc back to ToC or Class ToC

acetylsalicylic acid pharmacokinetics pathwayc back to ToC or Class ToC

acid and base sensing signaling pathwayc back to ToC or Class ToC

acid-base homeostasis pathwayc back to ToC or Class ToC

acid-base imbalance pathwayc back to ToC or Class ToC

acidosis pathwayc back to ToC or Class ToC

acrolein response pathwayc back to ToC or Class ToC

activin signaling pathwayc back to ToC or Class ToC

acute intermittent porphyria pathwayc back to ToC or Class ToC

acute myeloid leukemia pathwayc back to ToC or Class ToC

adaptive immune response pathwayc back to ToC or Class ToC

adefovir drug pathwayc back to ToC or Class ToC

adefovir pharmacodynamics pathwayc back to ToC or Class ToC

adefovir pharmacokinetics pathwayc back to ToC or Class ToC

adenine phoshoribosyltransferase deficiency pathwayc back to ToC or Class ToC

adenosine monophosphate deaminase deficiency pathwayc back to ToC or Class ToC

adenosine monophosphate-activated protein kinase (AMPK) signaling pathwayc back to ToC or Class ToC

adenosine signaling pathwayc back to ToC or Class ToC

adenosine triphosphate signaling pathwayc back to ToC or Class ToC

adenosine triphosphate signaling via the P2X ligand-gated ion channelc back to ToC or Class ToC

adenylosuccinate lyase deficiency pathwayc back to ToC or Class ToC

adiponectin signaling pathwayc back to ToC or Class ToC

ADP-ribosylation pathway, cyclic ribosylationc back to ToC or Class ToC

ADP-ribosylation pathway, mono and poly-ribosylationc back to ToC or Class ToC

adrenal gland disease pathwayc back to ToC or Class ToC

adrenergic beta receptor agonist and beta-blocker pharmacodynamics pathwayc back to ToC or Class ToC

adrenergic beta receptor agonist and beta-blocker pharmacokinetics pathwayc back to ToC or Class ToC

adrenergic beta receptor agonist drug pathwayc back to ToC or Class ToC

adrenergic beta receptor agonist drug pathwayc back to ToC or Class ToC

adrenergic beta receptor antagonist drug pathwayc back to ToC or Class ToC

adrenergic beta receptor drug pathway - beta agonistc back to ToC or Class ToC

adrenergic beta receptor drug pathway - beta-agonist and beta-blockerc back to ToC or Class ToC

adrenergic beta receptor non-selective agonist drug pathwayc back to ToC or Class ToC

1,1,1-trichloro-2,2-bis(4-chlorophenyl)ethane degradation pathway^c back to ToC or Class ToC

1,2-dichloroethane degradation pathway^c back to ToC or Class ToC

11-beta-hydroxylase deficiency pathway^c back to ToC or Class ToC

17-alpha-hydroxylase deficiency pathway^c back to ToC or Class ToC

2,4-dichlorobenzoate degradation pathway^c back to ToC or Class ToC

2-aminoadipic 2-oxoadipic aciduria pathway^c back to ToC or Class ToC

2-hydroxyglutaric aciduria pathway^c back to ToC or Class ToC

21-alpha-hydroxylase deficiency pathway^c back to ToC or Class ToC

3'-end pre-mRNA processing pathway^c back to ToC or Class ToC

3-chloroacrylic acid degradation pathway^c back to ToC or Class ToC

3-hydroxy-3-methylglutaryl-CoA lyase deficiency pathway^c back to ToC or Class ToC

3-hydroxyacyl-CoA dehydrogenase deficiency pathway^c back to ToC or Class ToC

3-hydroxyisobutyric aciduria pathway^c back to ToC or Class ToC

3-methylcrotonyl CoA carboxylase 1 deficiency pathway^c back to ToC or Class ToC

3-methylcrotonyl CoA carboxylase 2 deficiency pathway^c back to ToC or Class ToC

3-methylglutaconic aciduria type 1 pathway^c back to ToC or Class ToC

3-methylglutaconic aciduria type 3 pathway^c back to ToC or Class ToC

5'-end pre-mRNA capping pathway^c back to ToC or Class ToC

<new term>^c back to ToC or Class ToC

<new term>^c back to ToC or Class ToC

<new term>^c back to ToC or Class ToC

abacavir drug pathway^c back to ToC or Class ToC

abacavir pharmacodynamics pathway^c back to ToC or Class ToC

abacavir pharmacokinetics pathway^c back to ToC or Class ToC

abciximab drug pathway^c back to ToC or Class ToC

abciximab pharmacodynamics pathway^c back to ToC or Class ToC

abciximab pharmacokinetics pathway^c back to ToC or Class ToC

abscisic acid biosynthetic pathway^c back to ToC or Class ToC

abscisic acid metabolic pathway^c back to ToC or Class ToC

ACE inhibitor drug pathway^c back to ToC or Class ToC

ACE inhibitor pharmacodynamics pathway^c back to ToC or Class ToC

ACE inhibitor pharmacokinetics pathway^c back to ToC or Class ToC

acebutolol drug pathway^c back to ToC or Class ToC

acebutolol pharmacodynamics pathway^c back to ToC or Class ToC

acebutolol pharmacokinetics pathway^c back to ToC or Class ToC

acenocoumarol drug pathway^c back to ToC or Class ToC

acenocoumarol pharmacodynamics pathway^c back to ToC or Class ToC

acenocoumarol pharmacokinetics pathway^c back to ToC or Class ToC

acetylcholine metabolic pathway^c back to ToC or Class ToC

acetylcholine signaling pathway^c back to ToC or Class ToC

acetylcholine signaling pathway via muscarinic acetylcholine receptor^c back to ToC or Class ToC

acetylcholine signaling pathway via muscarinic acetylcholine receptors engaging G alphai protein family^c back to ToC or Class ToC

acetylcholine signaling pathway via muscarinic acetylcholine receptors engaging G alphaq protein family^c back to ToC or Class ToC

acetylcholine signaling pathway via nicotinic acetylcholine receptor^c back to ToC or Class ToC

acetylsalicylic acid drug pathway^c back to ToC or Class ToC

acetylsalicylic acid pharmacodynamics pathway^c back to ToC or Class ToC

acetylsalicylic acid pharmacokinetics pathway^c back to ToC or Class ToC

acid and base sensing signaling pathway^c back to ToC or Class ToC

acid-base homeostasis pathway^c back to ToC or Class ToC

acid-base imbalance pathway^c back to ToC or Class ToC

acidosis pathway^c back to ToC or Class ToC

acrolein response pathway^c back to ToC or Class ToC

activin signaling pathway^c back to ToC or Class ToC

acute intermittent porphyria pathway^c back to ToC or Class ToC

acute myeloid leukemia pathway^c back to ToC or Class ToC

adaptive immune response pathway^c back to ToC or Class ToC

adefovir drug pathway^c back to ToC or Class ToC

adefovir pharmacodynamics pathway^c back to ToC or Class ToC

adefovir pharmacokinetics pathway^c back to ToC or Class ToC

adenine phoshoribosyltransferase deficiency pathway^c back to ToC or Class ToC

adenosine monophosphate deaminase deficiency pathway^c back to ToC or Class ToC

adenosine monophosphate-activated protein kinase (AMPK) signaling pathway^c back to ToC or Class ToC

adenosine signaling pathway^c back to ToC or Class ToC

adenosine triphosphate signaling pathway^c back to ToC or Class ToC

adenosine triphosphate signaling via the P2X ligand-gated ion channel^c back to ToC or Class ToC

adenylosuccinate lyase deficiency pathway^c back to ToC or Class ToC

adiponectin signaling pathway^c back to ToC or Class ToC

ADP-ribosylation pathway, cyclic ribosylation^c back to ToC or Class ToC

ADP-ribosylation pathway, mono and poly-ribosylation^c back to ToC or Class ToC

adrenal gland disease pathway^c back to ToC or Class ToC

adrenergic beta receptor agonist and beta-blocker pharmacodynamics pathway^c back to ToC or Class ToC

adrenergic beta receptor agonist and beta-blocker pharmacokinetics pathway^c back to ToC or Class ToC

adrenergic beta receptor agonist drug pathway^c back to ToC or Class ToC

adrenergic beta receptor agonist drug pathway^c back to ToC or Class ToC

adrenergic beta receptor antagonist drug pathway^c back to ToC or Class ToC

adrenergic beta receptor drug pathway - beta agonist^c back to ToC or Class ToC

adrenergic beta receptor drug pathway - beta-agonist and beta-blocker^c back to ToC or Class ToC

adrenergic beta receptor non-selective agonist drug pathway^c back to ToC or Class ToC

adrenergic beta receptor non-selective antagonist drug pathway^c back to ToC or Class ToC

adrenergic beta receptor selective agonist drug pathway^c back to ToC or Class ToC